Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Dolutegravir Shows Significant Superior Efficacy Compared to Raltegravir in PIII Study: Shionogi
March 12, 2013
- Qol Senior Managing Director Takada Proposes Utilization of CSO for Long-Listed Products and Generics
March 11, 2013
- Nippon Shinyaku Licenses OAB Drug from DSP, Aims for Launch of Nocturia Treatment in 2019
March 11, 2013
- Takeda Files for UC and CD Drug Vedolizumab in Europe
March 11, 2013
- Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
- Ethical Drug Sales Up 4.8% in January: Crecon Report
March 11, 2013
- Astellas, UCB Japan Launch RA Treatment Cimzia
March 11, 2013
- NBI Calls for Proper Use of Prazaxa due to Unsatisfactory Compliance with Blue Letter
March 11, 2013
- Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
- Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
- With Growing Competition from Foreign Drug Makers, Takeda Interested in Product Tie-ups: President Hasegawa
March 8, 2013
- Yakult Enters Biosimilars Business, Ties Up with UMN and API
March 7, 2013
- Novartis Withdraws Application for Glivec for PAH in Japan
March 7, 2013
- Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
- Sawai's New Plant Starts Operation, Raising Annual Production Capacity to 8 Billion Tablets
March 6, 2013
- Nichi-Iko's New Factory Completed in Toyama, Production Capacity to Reach 7-8 Billion Tablets a Year
March 6, 2013
- DSP to Merge Its Clinical Development Functions with US Subsidiary’s
March 6, 2013
- Ranbaxy Resumes Production of Atorvastatin at US Plant
March 6, 2013
- 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
- Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…